开发了针对致癌性BCR::ABL1激酶的镜像单体
Nina Schmidt1, Amit Kumar1, Lukas Korf2
1Institute of Physiological Chemistry, Faculty of Medicine, Philipps University of Marburg, Marburg, Germany.
Nature communications
|December 23, 2024
概括
镜像D-单体由于稳定性和低免疫性而具有治疗潜力. 研究人员开发了向BCR::ABL1的强大的D-单体,证明了它们在抑制激酶活性方面的有效性.
科学领域:
- 生物化学 生物化学
- 蛋白质工程是指蛋白质工程.
- 治疗开发的治疗方法
背景情况:
- 镜像蛋白 (D-氨基酸) 提供治疗优势,如代谢稳定性和降低免疫性.
- 单体是可接受化学合成的合成结合蛋白.
- 向白血病氨酸激酶BCR::ABL1是癌症治疗的一个关键策略.
研究的目的:
- 开发具有对BCR::ABL1氨酸激酶的高度亲和度的镜像D-单体.
- 为了研究D-单体与其目标的结合方式.
- 评估D-单体的治疗潜力,包括它们的稳定性和抑制活性.
主要方法:
- D-的化学合成及其组装成D-单体.
- 菌体显示器用于选择L-结合剂与D-目标.
- 用X射线晶体学来确定单体-SH2复合物的结构.
- 生物化学测试以测量酶抑制和蛋白质酶抵抗.
主要成果:
- 开发出具有纳米分子结合亲和力的D-单体,用于BCR::ABL1.1的D-SH2域.
- 晶体结构揭示了一个非传统的结合模式,针对pY口袋.
- 合成的D-单体表现出蛋白酶耐药性,长期血稳定性和抑制BCR::ABL1激酶活性.
- 在细胞溶解物和透细胞中,D-单体成功结合了BCR::ABL1.
结论:
- 可以很容易地开发针对BCR::ABL1的功能D单体.
- 这些D-单体表现出治疗应用的理想特性,包括稳定性和目标抑制.
- 这些发现代表了D-单体在癌症治疗中的潜在使用的重大进展,在有效的细胞质输送方法之前.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K